Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose subcutaneous icatibant in pediatric hereditary angioedema
2011-003825-81Phase 4Completed
- Sponsor
- Takeda
- Start
- Nov 2011
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of icatibant in hereditary angioedema (HAE) (2 arms), sponsored by Takeda. Primary endpoints: Pharmacokinetic profile of icatibant after a single subcutaneous injection and Tolerability and safety of a single subcutaneous dose of icatibant. Started Nov 2011; status: completed.
02
Drugs
icatibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2011-003825-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003825-81.